Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-11-13
1999-03-30
Spivack, Phyllis G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31465
Patent
active
058890297
ABSTRACT:
Methods are provided for treating schizophrenia, Tourette's Syndrome, obsessive-compulsive disorder, substance abuse or substance addiction including drug or alcohol addiction, manic-depression syndrome, anexoria or bulimia comprising administering an amount of cotinine or a pharmaceutically acceptable salt thereof, which amount is effective to reduce or alleviate at least one of the symptoms of schizophrenia, Tourette's Syndrome, obsessive-compulsive disorder, substance abuse or substance addiction including drug or alcohol addiction, manic-depression syndrome, anexoria or bulimia in a human or other mammal.
REFERENCES:
patent: 3870794 (1975-03-01), Hutchinson et al.
patent: 4946853 (1990-08-01), Bannon et al.
patent: 5187169 (1993-02-01), Lippiello et al.
patent: 5298257 (1994-03-01), Bannon et al.
patent: 5596007 (1997-01-01), Keenan et al.
patent: 5612357 (1997-03-01), Keenan et al.
patent: 5643928 (1997-07-01), Keenan et al.
Freedman R., Hall M., Adler LE, Leonard S. "Evidence of Postmortem Brain Tissue for Decreased Numbers of Hippocampal Nicotinic Receptors in Schizophrenia", Biol. Psychiatry, 38(1):22-33 (1995).
Newhouse, P.A., Potter A., Corwin J., Lenox R., "Age-related Effects of the Nicotinic Antagonist Mecamylamine on Cognition and Behavior", Neuropsychopharmacology, 10(2): 93-107 (1994).
McConville B.J., Sanberg P.R., Fogelson M.H., et al. "The Effects of Nicotine Plus Haloperidol Compared to Nicotine Only and Placebo Nicotine Only in Reducing Tic Severity and Frequency in Tourette's Disorder", Biol. Psychiatry 31(8): 832-840 (1992).
Rosecrans JA. "The Role of Nicotine in Tobacco Dependence and Cessation", Chemistry and Industry, pp. 221-224 (Mar. 21, 1994).
Harmon James V.
LecTec Corporation
Spivack Phyllis G.
LandOfFree
Use of cotinine in treating psychiatric disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of cotinine in treating psychiatric disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of cotinine in treating psychiatric disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1215483